MedTrace Logo

Effect of Curcumin Addition to Standard Treatment on Tumour-induced Inflammation in Endometrial Carcinoma

NCT02017353 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2016-10-25

No results posted yet for this study

Summary

This therapy aims to determine whether curcumin can inhibit tumor induced inflammation in patients with endometrial carcinoma. In addition, curcumin could possibly induce a better functioning of chemotherapy and a decrease in toxicity from chemotherapy. Various studies have demonstrated that curcumin can have an effect on tumor growth and the development of metastases.

Conditions

  • Endometrial Carcinoma

Interventions

DIETARY_SUPPLEMENT

Curcuphyt

Sponsors & Collaborators

  • Reliable Cancer Therapies

    collaborator INDUSTRY

  • University Hospital, Gasthuisberg

    lead OTHER

Principal Investigators

  • Frederic Amant, MD, PhD · UZ Leuven

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2016-05-31
Completion
2016-10-31

Countries

  • Belgium

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02017353 on ClinicalTrials.gov